Movers and SHAKERS
|Current Price||$3.34 ↑ 0.11|
|52wk Range||$0.78 - $3.42|
|ADVANCED MARKET DATA|
Advanced Market DataCitius Pharmaceuticals Inc. (CTXR)
11 Commerce Drive
Cranford, NJ 7016
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) finds itself up over 15% going into Tuesday’s market close after the Company announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), effective immediately.
Dr. Laffey joins a ARDS Scientific Advisory Board replete with noted colleagues, including Dr. Michael A. Matthay, Professor of Medicine and Anesthesia at the University of California at San Francisco (UCSF); Dr. Lorraine B. Ware, Professor of Medicine and Ralph and Lulu Owen Endowed Chair; and Dr. Perenlei Enkhbaatar, Charles Robert Allen Professor of Anesthesiology at The University of Texas Medical Branch.
Each member of the Board is a recognized key opinion leader with extensive clinical trial expertise in the treatment of acute lung disorders with Myron Holubiak, President and Chief Executive Officer of Citius, speaking highly of the Board’s newest addition, “Dr. Laffey is a highly accomplished and recognized expert in acute lung disorders. His cutting-edge research into the use of gene and stem cell-based therapies to treat ARDS will provide Citius with an important perspective as we explore the potential of this exciting new therapeutic area.”
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy.
The post Citius Pharmaceuticals, Inc. Expands Scientific Advisory Board first appeared on Financial Buzz .
For further details see:Citius Pharmaceuticals, Inc. Expands Scientific Advisory Board
Citius Pharmaceuticals Inc. Corporate Filings
Citius Pharmaceuticals Inc. Corporate Events
Citius Pharmaceuticals Inc. Press Releases / News Feed
No reports available